3 Undervalued Biotechnology Stocks for Monday, November 09
Discover the top 3 undervalued Biotechnology stocks for Monday, November 09 based on AAII’s Stock Grades.Michael Rose
| SECTOR | INDUSTRY |
| Health Care | Biotechnology |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Michael Rose
Rosalio Madrigal
Michael Rose
Rosalio Madrigal
Jenna Brashear
| Share Statistics | BCRX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,878.3 | $213.9 | 55% |
|
| Shares Out (Mil) | 267.6 | 55.4 | 81% |
|
| Institutional Ownership | 99.0% | 93.3% | 83% |
|
| Float (Mil) | 239.5 | 40.6 | 76% |
|
| Beta | 0.51 | 0.98 | 28% |
|
| Avg Daily Volume (000s) | 4,965 | 597 | 91% |
|
| Price Change (52-week) |
3.8% | 40.9% | 54% |
|
| Growth | BCRX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 117.9% | 13.2% | 99% |
|
| Net Income (5yr) | 28.1% | (10.7%) | 83% |
|
| EPS (5yr) | 25.4% | 15.5% | 76 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (15.7%) | (15.7%) | 47% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 2 | 2 | 2 | |
| Current EPS | $0.100 | $0.865 | $0.855 | |
| Month Ago EPS | $0.125 | $0.745 | $0.940 | |
| # Rev Up | 0 | 0 | 2 | |
| # Rev Down | 1 | 1 | 0 | |
| Three Months Ago EPS | $0.125 | $0.745 | $0.940 | |
| Year/Year Chg | (28.6%) | (28.5%) | 2.9% | |
| Financials | BCRX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $962 | $39 | 49% |
|
| Net Income (TTM) (Mil) | ($360) | ($44) | 4% |
|
| EPS (TTM) | ($1.493) | ($1.400) | 17% |
|
| Operating Cash Flow (TTM) (Mil) | $368 | ($34) | 67% |
|
| Net Cash Flow (TTM) (Mil) | ($3) | $-0 | 39% |
|
| Long-Term Debt (Q1) (Mil) | $781 | $4 | 63% |
|
| Enterprise Value (Q1) (Mil) | $2,411 | $135 | 52% |
|
| Valuation | BCRX | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 1.97 | na |
|
| P/E | na | 17.6 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 0.8 | na |
|
| Ratios | BCRX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 78.1% | 67.9% | 87% |
|
| Net Margin | (37.4%) | (50.8%) | 13% |
|
| ROA | (69.3%) | (47.5%) | 8% |
|
| ROE | 91.6% | (51.9%) | 96% |
|
| Liabilities to Assets | 167.2% | 29.7% | 99% |
|
| F-Score | 5 | 3 | na |
|
BioCryst Pharmaceuticals, Inc. did not pass any screens on 11/18/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors